In a randomized phase 3 AML‐10 trial of European Organization for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) in 292 patients with AML in CR1, it showed that higher number of mobilized CD34+ cells were associated with higher RR irrespective of treatment with ASCT or autologous BMT.45 The gene discussed is CD34; the disease is acute myeloid leukemia.